EHA 2026 | Linvoseltamab demonstrates deep responses in relapsed/refractory multiple myeloma

Linvoseltamab is a new BCMA-specific antibody, anti-BCMA CD3, and this is really interesting because I think that this gives, according to clinical trials, fast response and deep response. This is particularly important in terms of time to response that in aggressive relapse can be an important key point, balanced with a very good rate of MRD negativity, more than 90% in patients achieving complete response. Moreover, also the dose density is not too high, and particularly inside the registrative trial, MM1, patients arriving at 24 months, achieving at least a very good partial response, can reduce the schedule, can switch to every two weeks to a monthly administration, also improving the response, and this is an important key point. The rates of CRS and ICANS are particularly manageable, they are never irate, always reversible. And we have never seen in our experience inside the clinical trials big adverse events that took the patient to withdraw. I think that this is really interesting in monotherapy as it’s going to be approved also in our country. It is FDA approved and we are waiting for reimbursement, but also in perspective, because there are ongoing several clinical trials with the limbo-based treatment. And I’m particularly excited about the phase 3 in combination with carfilzomib, in which I think that we can find a new doublet that can be a potential game changer. And moreover, there are ongoing clinical trials about Linvoseltamab in smoldering myeloma, low intermediate risk, a phase two, and high risk in which Linvoseltamab is being compared with daratumumab. These are really interesting trials, also from the linker family of clinical trials in which our end point is MRD negativity. And I think that MRD negativity is becoming particularly in smoldering myeloma the real end point. We should eradicate, we should dream to cure this patient. The idea to cure citizens, they are not patients before they get ill, before they get symptoms. And I think that the key point is to find a really effective drug, really fast response with a very good tolerability. Livoseltamab can be a key solution for this patient. Waiting for the results also in earlier lines of multiple myeloma. I think that Limv will be a molecule about which we will listen to a lot of good things and I look forward to having not only in clinical trials but also in my daily practice.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.